Loading
DLL4 (Delta-like protein 4) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Involved in the Notch signalling pathway as Notch ligand. Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting.
Open Targets scores its association with cancer at 0.60 (direct and indirect evidence; datatypes clinical 0.18, affected pathway 0.91, literature 0.98, genetic association 0.00, animal model 0.26). In OnCo, 1 product record names it (Tovecimig).
In plain words · DLL4 (Delta-like protein 4) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
DLL4 (Delta-like protein 4) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Involved in the Notch signalling pathway as Notch ligand. Activates NOTCH1 and NOTCH4.
No product in this corpus aims at DLL4 yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Tumour-associated overexpression: 1 antibody (Tovecimig) aim at the antigen, which HPA finds with no normal tissue stained high; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA DLL4: RNA low tissue specificity; no normal tissue stained high. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas DLL4 tissue; Human Protein Atlas DLL4 pathology; Open Targets ENSG00000128917 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Shutter J.R. et al, Genes Dev, 2000, "Dll4, a novel Notch ligand expressed in arterial endothelium". Source.
Sources: HGNC HGNC:2910 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NR61 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000128917 (association with cancer (MONDO_0004992) 0.60; (GraphQL API, CC0))
Involved in the Notch signalling pathway as Notch ligand. Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types. During spinal cord neurogenesis, inhibits V2a interneuron fate. Location: Cell membrane (UniProt). Locus 15q15.1 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Kidney Renal Clear Cell Carcinoma 41 pTPM.
No cancer stained high; medium in breast cancer, carcinoid, endometrial cancer, melanoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"DLL4" OR ABSTRACT:"DLL4" OR TITLE:"delta like canonical Notch ligand 4" OR ABSTRACT:"delta like canonical Notch ligand 4" OR TITLE:"Delta-like protein 4" OR ABSTRACT:"Delta-like protein 4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DLL4, not a curated reading list.